Acasti Pharma Class A (NASDAQ:ACST) Shorted Shares Increased By 716.34%

January 10, 2018 - By Darrin Black

 Acasti Pharma Class A (NASDAQ:ACST) Shorted Shares Increased By 716.34%

The stock of Acasti Pharma Class A (NASDAQ:ACST) registered an increase of 716.34% in short interest. ACST’s total short interest was 454,700 shares in January as published by FINRA. Its up 716.34% from 55,700 shares, reported previously. With 2.46M shares average volume, it will take short sellers 0 days to cover their ACST’s short positions. The short interest to Acasti Pharma Class A’s float is 7.8%.

The stock 0.01% or $0 during the last trading session, reaching $0.95. It is down 3.13% since January 10, 2017 and is downtrending. It has underperformed by 19.83% the S&P500.

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. The company has market cap of $13.82 million. The company's lead product candidate is CaPre, an omega-3 phospholipid for the treatment of hypertriglyceridemia. It currently has negative earnings.

More notable recent Acasti Pharma Inc. (NASDAQ:ACST) news were published by: Marketwired.com which released: “Acasti Pharma Announces Issuance of Common Shares in Payment of Outstanding …” on January 08, 2018, also Marketwired.com with their article: “Acasti Pharma and CordenPharma Announce Large Scale Production of CaPre® with …” published on May 31, 2017, Marketwatch.com published: “Acasti Pharma Inc.” on November 28, 2016. More interesting news about Acasti Pharma Inc. (NASDAQ:ACST) were released by: Marketwired.com and their article: “Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock …” published on August 17, 2017 as well as Seekingalpha.com‘s news article titled: “Acasti Pharma advancing potential deal to commercialize CaPre in Asia; shares …” with publication date: November 20, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.